Literature DB >> 30454914

The Case Against the European Medicines Agency's Change to the Label for Radium-223 for the Treatment of Metastatic Castration-resistant Prostate Cancer.

Joe M O'Sullivan1, Daniel Heinrich2, Nicholas D James3, Sten Nilsson4, Piet Ost5, Christopher C Parker6, Bertrand Tombal7.   

Abstract

Entities:  

Year:  2018        PMID： 30454914     DOI： 10.1016/j.eururo.2018.11.003

Source DB:  PubMed          Journal:  Eur Urol        ISSN： 0302-2838            Impact factor:   20.096


× No keyword cloud information.
  5 in total

1.  Clinical aspects of mCRPC management in patients treated with radium-223.

Authors:  Elisa Lodi Rizzini; Valeria Dionisi; Pietro Ghedini; Alessio Giuseppe Morganti; Stefano Fanti; Fabio Monari
Journal:  Sci Rep       Date:  2020-04-21       Impact factor: 4.379

2.  Radium 223 combined with new hormone therapies for the treatment of castrate-resistant metastatic prostate cancer: scientific evidence and sharing of our experience.

Authors:  Miguel E Jiménez-Romero; Elba Y Canelón-Castillo; Sara Díez-Farto; Jose D Santotoribio
Journal:  Transl Androl Urol       Date:  2019-10

3.  Scintigraphic load of bone disease evaluated by DASciS software as a survival predictor in metastatic castration-resistant prostate cancer patients candidates to 223RaCl treatment.

Authors:  Viviana Frantellizzi; Arianna Pani; Maria Dea Ippoliti; Alessio Farcomeni; Irvin Aloise; Mirco Colosi; Claudia Polito; Roberto Pani; Giuseppe De Vincentis
Journal:  Radiol Oncol       Date:  2019-12-19       Impact factor: 2.991

Review 4.  Radium-223 mechanism of action: implications for use in treatment combinations.

Authors:  Michael J Morris; Eva Corey; Theresa A Guise; James L Gulley; William Kevin Kelly; David I Quinn; Arne Scholz; George Sgouros
Journal:  Nat Rev Urol       Date:  2019-11-11       Impact factor: 14.432

Review 5.  The Role of Theranostics in Prostate Cancer.

Authors:  Elisabeth O'Dwyer; Lisa Bodei; Michael J Morris
Journal:  Semin Radiat Oncol       Date:  2021-01       Impact factor: 5.934
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.